Back to top
more

Solid Biosciences (SLDB)

(Real Time Quote from BATS)

$4.93 USD

4.93
240,689

-0.38 (-7.16%)

Updated Nov 15, 2024 03:05 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value C Growth F Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 29% (72 out of 250)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Pfizer (PFE) Begins Dosing in DMD Study With Gene Therapy

by Zacks Equity Research

Pfizer (PFE) doses the first participant in the phase III CIFFREO study, evaluating its investigational gene therapy, PF-06939926, for treating boys with DMD.

Sarepta (SRPT) Down on Unsatisfactory Data for DMD Candidate

by Zacks Equity Research

Sarepta (SRPT) posts top-line results from part 1 of Study 102, evaluating a single dose of its gene therapy candidate SRP-9001 for treating DMD. Shares fall.

Ultragenyx (RARE) Surges on Product Approvals, Pipeline Progress

by Zacks Equity Research

Ultragenyx (RARE), which has a strong pipeline, receives a few approvals for its products in 2020.

New Strong Sell Stocks for December 9th

by Zacks Equity Research

Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today

Sarepta (SRPT) DMD Study Shows Proof of Concept for SRP-5051

by Zacks Equity Research

Sarepta's (SRPT) ongoing phase II study data supports continued dose escalation of SRP-5051 and suggests improved efficacy on lower doses compared to Exondys 51.

Are Options Traders Betting on a Big Move in Solid Biosciences (SLDB) Stock?

by Zacks Equity Research

Investors need to pay close attention to Solid Biosciences (SLDB) stock based on the movements in the options market lately.

Solid Biosciences (SLDB) Reports Wider-Than Expected Q3 Loss

by Zacks Equity Research

Solid Biosciences??? (SLDB) reports wider than expected loss in the third quarter of 2020.

Solid Biosciences (SLDB) to PostQ3 Earnings: What's in Store?

by Zacks Equity Research

Solid Biosciences (SLDB) will provide updates on its lead pipeline candidate,SGT-001, along with others when it releases third-quarter 2020 results.

Do Options Traders Know Something About Solid Biosciences (SLDB) Stock We Don't?

by Zacks Equity Research

Investors need to pay close attention to Solid Biosciences (SLDB) stock based on the movements in the options market lately.

Sarepta's Casimersen NDA Gets Priority Review From FDA

by Zacks Equity Research

Sarepta (SRPT) is seeking accelerated approval for exon 45 amenable DMD candidate, casimersen. Amondys 45 is likely to be the brand name for the candidate.

Sarepta Completes Rolling NDA Submission for New DMD Therapy

by Zacks Equity Research

Sarepta (SRPT) is seeking accelerated approval for its third exon-skipping therapy, casimersen, for DMD patients.

Sarepta Inks Agreement With Codiak to Develop Gene Therapies

by Zacks Equity Research

Sarepta (SRPT) and Codiak BioSciences sign agreement to develop potential gene therapies targeting neuromuscular indications using Codiak's engineered exosomes.

Sarepta's Gene Therapy Promising in Muscular Dystrophy Study

by Zacks Equity Research

Sarepta's (SRPT) gene therapy candidate for treating limb-girdle muscular dystrophy shows continued functional improvement over a year for the lower dose as well as increasing efficacy with higher dose.

Why Solid Biosciences (SLDB) Stock Might be a Great Pick

by Zacks Equity Research

Solid Biosciences (SLDB) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

Pfizer Reports Efficacy & Safety Data on DMD Gene Therapy

by Zacks Equity Research

Pfizer's (PFE) new phase Ib data on its investigational gene therapy, PF-06939926 in ambulatory boys with DMD support advancement to a pivotal phase III study.

Top Ranked Momentum Stocks to Buy for May 13th

by Zacks Equity Research

Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, May 13th.

Applied Genetic Stock Up on Favorable Eye Therapy Study Data

by Zacks Equity Research

Applied Genetic's (AGTC) gene therapy candidate shows promise in an early-stage study to treat X-linked retinitis pigmentosa, a rare eye disorder.

Sarepta Signs Gene Therapy Agreement With Roche for $1.15B

by Zacks Equity Research

Sarepta (SRPT) grants ex-U.S. marketing rights of its gene therapy DMD candidate, SRP-9001, to Roche for an upfront payment of $1.15 billion. Sarepta is also eligible to receive $1.7 billion in milestone payments.

Options Traders Expect Huge Moves in Solid Biosciences (SLDB) Stock

by Zacks Equity Research

Investors need to pay close attention to Solid Biosciences (SLDB) stock based on the movements in the options market lately.

Sarepta's Vyondys 53 Receives FDA Approval for DMD, Stock Up

by Zacks Equity Research

Sarepta (SRPT) exon-53 skipping DMD drug, Vyondys 53, gets approval in the United States following a CRL in August.

Biotech Stock Roundup: SLDB Plunges, CELG Gets FDA Nod for Reblozyl & Other Updates

by Zacks Equity Research

Key highlights of the past week include regulatory and pipeline updates along with collaboration deals.

Will Solid Biosciences Continue to Surge Higher?

by Zacks Equity Research

As of late, it has definitely been a great time to be an investor Solid Biosciences.

Sarepta Stock Falls as FDA Denies Approval to Golodirsen

by Zacks Equity Research

The CRL to golodirsen NDA comes as a surprise for Sarepta (SRPT) and investors as no issues were raised by the FDA during the review period that could have lead to non-approval of the candidate.

    Solid Biosciences Surges on DMD Gene Therapy Study Amendments

    by Zacks Equity Research

    Solid Biosciences (SLDB) amends its phase I/II gene therapy study protocol to expedite the development of its lead candidate, SGT-001, as potential treatment for DMD.

    Sarepta (SRPT) Q2 Loss Widens Y/Y, Golodirsen Nears Approval

    by Zacks Equity Research

    Sarepta (SRPT) reports wider year-over-year loss. However, revenues increase year over year. The company plans expansion of gene therapy program into other indications including multiple sclerosis.